5-t-butyl-2-mercaptopyrimidine | 96412-31-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-t-butyl-2-mercaptopyrimidine
• 英文别名: 5-tert-butyl-1H-pyrimidine-2-thione
• CAS: 96412-31-6
• 化学式: C₈H₁₂N₂S
• 分子量: 168.263
• InChiKey: FJCBOBNSXNQHEG-UHFFFAOYSA-N

物化性质

• 沸点：
  239.0±23.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  56.5
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-t-butyl-2-mercaptopyrimidine 、 molybdenum hexacarbonyl 以 1,2,5-trimethyl-benzene 为溶剂， 生成 tetrakis(5-tert-butyl-2-mercaptopyrimidinato)molybdenum(IV)
  参考文献：
  名称：

  Donahue, Craig J.; Martin, A. Van; Schoenfelner, Barry A., Inorganic Chemistry, 1991, vol. 30, # 7, p. 1588 - 1594

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF LEUCINE RICH REPEAT KINASE 2<br/>[FR] INHIBITEURS DE LA KINASE 2 À RÉPÉTITION RICHE EN LEUCINE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019012093A1

  公开（公告）日：2019-01-17

  The present invention relates to novel compounds that inhibit LRRK2 kinase activity, to processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

  本发明涉及抑制LRRK2激酶活性的新化合物，以及它们的制备方法、含有它们的组合物，以及它们在治疗或预防与LRRK2激酶活性相关或以其为特征的疾病中的应用，例如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症（ALS）。
• Donahue, Craig J.; Kosinski, Ellen C.; Van Martin, Inorganic Chemistry, 1985, vol. 24, # 13, p. 1997 - 2003
  作者：Donahue, Craig J.、Kosinski, Ellen C.、Van Martin

  DOI：——

  日期：——
• INHIBITORS OF LEUCINE RICH REPEAT KINASE 2
  申请人：GlaxoSmithKline Intellectual Property Development Ltd

  公开号：EP3652179A1

  公开（公告）日：2020-05-20
• ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20190023729A1

  公开（公告）日：2019-01-24

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an aryl, heteroaryl or heterocycle (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.